Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors

Eur J Cancer. 2007 Nov;43(17):2621-7. doi: 10.1016/j.ejca.2007.08.031. Epub 2007 Oct 22.

Abstract

Cancer testis tumour associated antigens (C/T-TAAs) were investigated in several gynaecologic and non-gynaecologic neoplasms as possible prognostic markers and targets for immunotherapy. The objective of the present study was to evaluate C/T-TAA expression patterns and prognostic significance in patients affected by vulvar cancer. Melanoma antigen E (MAGE)-A1, MAGE-A4 and NY-ESO-1 expression was determined by immunohistochemistry in paraffin-embedded tissue specimens from 45 primary and 14 recurrent vulvar carcinomas treated with surgery. MAGE-A1, MAGE-A4 and NY-ESO-1 were expressed in 25 (42%), 38 (64%) and 40 (68%) of the 59 samples, respectively. MAGE-A4 was significantly more frequently expressed in tumours with lymph node metastases (p<0.002) and in recurrent tumours (p<0.02). NY-ESO-1 was more highly expressed by moderately or poorly differentiated tumours (p<0.01). This study demonstrates that vulvar cancer frequently expresses C/T-TAAs. Antigen expression correlates with the presence of lymph node metastases and poor tumour differentiation.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm / metabolism*
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Melanoma-Specific Antigens
  • Membrane Proteins / metabolism*
  • Middle Aged
  • Neoplasm Proteins / metabolism
  • Neoplasm Recurrence, Local / metabolism*
  • Prognosis
  • Vulvar Neoplasms / metabolism*

Substances

  • Antigens, Neoplasm
  • CTAG1B protein, human
  • MAGEA1 protein, human
  • MAGEA4 protein, human
  • Melanoma-Specific Antigens
  • Membrane Proteins
  • Neoplasm Proteins